MAGENTIQ-COLO™
AI-powered decision support platform for colonoscopy with real-time CADe and CADx capabilities
Software · EmbeddedCompany source
Company profile
About Magentiq Eye LTD
Magentiq Eye is a medical software company focused on advancing gastrointestinal endoscopy through artificial intelligence. Founded in 2014 and headquartered in Haifa, Israel, the company develops AI-powered decision support solutions designed to enhance colonoscopy performance, improve procedural quality, and support better clinical outcomes without disrupting physician workflow. Their flagship platform, MAGENTIQ-COLO™, combines real-time Computer-Aided Detection (CADe) and Computer-Aided Diagnosis (CADx) capabilities to assist gastroenterologists during colonoscopy procedures with polyp detection, characterization, procedural quality metrics, and AI-generated reporting. The platform is FDA-cleared and CE-marked, with capabilities tailored to different regulatory markets. MAGENTIQ-COLO™ has demonstrated strong clinical performance in a large international multicenter randomized trial published in The Lancet Digital Health, showing a 26% relative increase in adenoma detection rate (ADR) and a 48% reduction in adenoma miss rate (AMR) compared to standard colonoscopy. The technology is used by leading gastroenterology centers and healthcare providers worldwide. The company's mission is to help raise the global standard of gastrointestinal care through clinically validated, practical, and high-performance AI solutions. Magentiq Eye is expanding its platform beyond colonoscopy into additional gastrointestinal applications, including upper GI quality metrics and advanced diagnostic support tools, subject to regulatory approvals.
Company description Magentiq Eye LTD official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Magentiq Eye LTD?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Adenomas
- Colorectal polyps
- Gastrointestinal conditions
- Upper GI conditions
Who it serves
- Endoscopy clinics
- Gastroenterology centers
- Healthcare providers
- Hospitals
Deployment & integration
Embedded deployment with recorded integration context.
Geographic context
MarketsGlobal expansion underway · International
Company sourceOfficial website
Company milestones
Platform expansion
Preparing to launch Upper GI landmark detection application for standardizing examinations and improving procedural quality; expanding platform beyond colonoscopy into additional GI applications
Partnerships
Recorded partners
- Leading gastroenterology centers and healthcare providers globally
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Upper GI Landmark Detection Application
AI application for standardizing upper GI examinations and improving procedural quality
Software · EmbeddedCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
MAGENTIQ-COLO (ME-APDS)K252178 · 510k · Oct 3, 2025
MAGENTIQ-COLO (ME-APDS)K244023 · 510k · Jan 24, 2025
ME-APDS; MAGENTIQ-COLOK223473 · 510k · Jul 25, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
26% relative increase in adenoma detection rate (ADR)
Compared to standard colonoscopy in multicenter RCT
48% reduction in adenoma miss rate (AMR)
Compared to standard colonoscopy in multicenter RCT
7% absolute increase in ADR
Published in Lancet Digital Health
International Multicenter Study
Improving adenoma detection and reducing miss rates during colonoscopy procedures
26% relative increase in adenoma detection rate (ADR) and 48% reduction in adenoma miss rate (AMR); 7% absolute increase in ADR
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Dror Zur
CEO
06 · Company updates
Updates from Magentiq Eye LTD
Recent articles published on Magentiq Eye LTD's official website.
Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs
Read on Magentiq Eye LTDPatient Group Sues AMA, Says the Org Shouldn’t Be Charging for CPT Codes
Read on Magentiq Eye LTDHospitals Have Always Had Eyes — AI is Giving Them a Brain
Read on Magentiq Eye LTDThe Healthcare Inflection Point: AI Can’t Fix 1990s Technology
Read on Magentiq Eye LTDHealing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands
Read on Magentiq Eye LTD07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.